FindMyKOL

Ezra Cohen, MD

Enriched profile

Chief Medical Officer at Tempus Labs Inc. · UC San Diego Health

ORCIDNone on fileNPI↗
✓ Itemized profile
Region🇺🇸 San Diego, CA · West · United StatesSpecialtyHematology / OncologyFocusHead & Neck Cancer+5
Active KOLFindMyKOL type: NationalLatest publicationNone indexedOnline presenceNone verifiedPayments2021–2025NIH funding2017–2023Why? →

Ezra Cohen is Chief Medical Officer at Tempus Labs Inc. at UC San Diego Health. ClinicalTrials.gov lists 17 registered studies with this person as an investigator.

Data verified 13 Nov 2026

Overview

Updated 17 Nov 2026

Ezra Cohen, MD, is Chief Medical Officer at Tempus Labs Inc. at UC San Diego Health. It also documents an investigator role on 17 registered clinical trials, industry payments reported by 27 companies, 5 NIH-funded awards (2017–2023).

  • Top research focus: Head & Neck Cancer
  • 17 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 27 companies

Generated from the cited public record · current as of 17 Nov 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Head & Neck Cancer7 trialsCarcinoma, Squamous Cell6 trialsMelanoma2 trialsEsophageal Neoplasms1 trialGastroesophageal Cancer1 trialGastrointestinal Neoplasms1 trial

Research focus

OpenAlex concept fingerprint
Head & Neck CancerCarcinoma, Squamous CellMelanomaEsophageal NeoplasmsGastroesophageal CancerNeoplasm Metastasis

Drugs & molecules

across trials, industry payments and publications
Keytrudageneric · PembrolizumabClinical trials—Industry payments11Publications—Lenvimageneric · LenvatinibClinical trials—Industry payments6Publications—Libtayogeneric · CemiplimabClinical trials—Industry payments3Publications—Erbituxgeneric · CetuximabClinical trials—Industry payments2Publications—Tecentriqgeneric · AtezolizumabClinical trials—Industry payments2Publications—Cabometyxgeneric · CabozantinibClinical trials—Industry payments1Publications—Mavencladgeneric · CladribineClinical trials—Industry payments1Publications—Padcevgeneric · EnfortumabClinical trials—Industry payments1Publications—Tivdakgeneric · TisotumabClinical trials—Industry payments1Publications—Udenycageneric · PegfilgrastimClinical trials—Industry payments1Publications—Vitrakvigeneric · LarotrectinibClinical trials—Industry payments1Publications—

Works with

trial sponsors and companies reporting payments
Merck Sharp & Dohme LLCClinical trials—Industry payments22Merck KGaAClinical trials—Industry payments9Merck Sharp & Dohme CorporationClinical trials—Industry payments9Regeneron Pharmaceuticals, Inc.Clinical trials—Industry payments9University of ChicagoClinical trials8Industry payments—Eisai Inc.Clinical trials—Industry payments7Abbvie Inc.Clinical trials—Industry payments5F. Hoffmann-La Roche AGClinical trials—Industry payments4Regeneron Healthcare Solutions, Inc.Clinical trials—Industry payments3AVEO Pharmaceuticals, Inc.Clinical trials—Industry payments2Ipsen Bioscience IncClinical trials—Industry payments2National Cancer Institute (NCI)Clinical trials2Industry payments—Assuntina G. Sacco, MDClinical trials1Industry payments—Astellas Pharma Global DevelopmentClinical trials—Industry payments1AstraZenecaClinical trials1Industry payments—AstraZeneca UK LimitedClinical trials—Industry payments1Bayer HealthCare Pharmaceuticals Inc.Clinical trials—Industry payments1Boehringer Ingelheim International GmbHClinical trials—Industry payments1CelgeneClinical trials1Industry payments—Cidara Therapeutics, Inc.Clinical trials—Industry payments1Coherus Biosciences Inc.Clinical trials—Industry payments1Dynavax Technologies CorporationClinical trials1Industry payments—Eli Lilly and CompanyClinical trials—Industry payments1Exelixis Inc.Clinical trials—Industry payments1Ezra CohenClinical trials1Industry payments—Genmab U.S., Inc.Clinical trials—Industry payments1GlaxoSmithKline, LLC.Clinical trials—Industry payments1Gregory DanielsClinical trials1Industry payments—Janssen Global Services, LLCClinical trials—Industry payments1Janssen Research & Development, LLCClinical trials—Industry payments1

Scholarship

indexed output and impact (OpenAlex)
View publications ↓

Research metrics need a complete publication history and a confident author match. We omit them when either check fails. Why? →

Clinical & industry

trials, payments and federal funding
17clinical trials

Investigator role on registered studies.

View trials ↓
27companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
5NIH grants · 2017–2023

Federally funded research awards.

View funding ↓

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 13 Nov 2026

Listed as an investigator on 17 registered studies on ClinicalTrials.gov. The most recent:

Industry payments

Updated 13 Nov 2026

27 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cancer & immunology

    62.2%
    Kinase inhibitor62.2%
    Mekinist50%Tafinlar50%
    Part D<11 patients
  • Hormonal (systemic)

    37.8%
    l-Thyroxine37.8%
    Levothyroxine Sodium100%
    Part D<11 patients
Where care is delivered (Part B)100% facility · 0% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

Updated 13 Nov 2026

5 NIH research awards on record, funded 2017–2023 per NIH RePORTER. The latest:

All 46 award records: search, sort and filter.Explore →

Publications

None on file yet. We only list publications we can confidently match to this person. Why? →

Online presence

Updated 13 Nov 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Mentions by others

where others cite or feature them
  • Other

    iem.ucsd.edu/researchers/people/profiles/ezra-cohen.html

    verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →iem.ucsd.edu ↗
  • Other

    pmto.ucsd.edu/faculty/cohen-ezra.html

    verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →pmto.ucsd.edu ↗
  • Other

    providers.ucsd.edu/details/22401/medical-oncology-cancer

    verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →providers.ucsd.edu ↗
  • YouTube

    youtube.com/watch

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 13 Nov 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record
  • Medical degree (MD)

    University of Toronto

    verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →providers.ucsd.edu ↗

Editorial & leadership roles

journal and society appointments
  • Editor-in-Chief

    Oral Oncology

    verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →providers.ucsd.edu ↗
  • Chair

    National Cancer Institute (NCI) Head and Neck Cancer Steering Committee

    verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →providers.ucsd.edu ↗
  • verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →providers.ucsd.edu ↗
  • Fellow

    Royal College of Physicians and Surgeons of Canada (FRCPSC)

    verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →providers.ucsd.edu ↗
  • Fellow

    American Society of Clinical Oncology (FASCO)

    verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →providers.ucsd.edu ↗
  • Member

    Protocol Review and Monitoring Committee (PRMC), Moores Cancer Center

    verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →iem.ucsd.edu ↗
  • verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →iem.ucsd.edu ↗

Secondary affiliations

appointments beyond the home institution
  • Co-Director

    Hanna and Mark Gleiberman Head and Neck Cancer Center, Moores Cancer Center

    verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →iem.ucsd.edu ↗
  • Co-Director

    IEM Center for Engineering in Cancer, UC San Diego Health

    verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →iem.ucsd.edu ↗

Media & interviews

press, podcasts and appearances

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.